Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report released on Wednesday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of EGRX stock opened at $3.96 on Wednesday. The business’s fifty day moving average price is $4.70 and its 200 day moving average price is $4.74. Eagle Pharmaceuticals has a 1-year low of $3.21 and a 1-year high of $15.91. The firm has a market capitalization of $51.43 million, a PE ratio of 3.36 and a beta of 0.53.

Institutional Trading of Eagle Pharmaceuticals

Several large investors have recently bought and sold shares of the company. AIGH Capital Management LLC lifted its position in shares of Eagle Pharmaceuticals by 2.1% in the second quarter. AIGH Capital Management LLC now owns 1,211,509 shares of the specialty pharmaceutical company’s stock valued at $6,784,000 after acquiring an additional 25,000 shares in the last quarter. Vanguard Group Inc. lifted its position in Eagle Pharmaceuticals by 0.4% during the first quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock worth $3,358,000 after buying an additional 2,630 shares during the period. Los Angeles Capital Management LLC lifted its position in Eagle Pharmaceuticals by 110.1% during the first quarter. Los Angeles Capital Management LLC now owns 191,732 shares of the specialty pharmaceutical company’s stock worth $1,005,000 after buying an additional 100,470 shares during the period. Perceptive Advisors LLC purchased a new position in Eagle Pharmaceuticals during the second quarter worth about $971,000. Finally, Trexquant Investment LP lifted its position in Eagle Pharmaceuticals by 88.0% during the fourth quarter. Trexquant Investment LP now owns 126,282 shares of the specialty pharmaceutical company’s stock worth $660,000 after buying an additional 59,095 shares during the period. Institutional investors and hedge funds own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.